GB202204070D0 - Treatment - Google Patents

Treatment

Info

Publication number
GB202204070D0
GB202204070D0 GBGB2204070.3A GB202204070A GB202204070D0 GB 202204070 D0 GB202204070 D0 GB 202204070D0 GB 202204070 A GB202204070 A GB 202204070A GB 202204070 D0 GB202204070 D0 GB 202204070D0
Authority
GB
United Kingdom
Prior art keywords
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2204070.3A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exvastat Ltd
Original Assignee
Exvastat Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exvastat Ltd filed Critical Exvastat Ltd
Priority to GBGB2204070.3A priority Critical patent/GB202204070D0/en
Publication of GB202204070D0 publication Critical patent/GB202204070D0/en
Priority to PCT/EP2023/057432 priority patent/WO2023180431A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB2204070.3A 2022-03-23 2022-03-23 Treatment Ceased GB202204070D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2204070.3A GB202204070D0 (en) 2022-03-23 2022-03-23 Treatment
PCT/EP2023/057432 WO2023180431A1 (en) 2022-03-23 2023-03-23 Imatinib for use in the treatment of acute respiratory distress syndrome

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2204070.3A GB202204070D0 (en) 2022-03-23 2022-03-23 Treatment

Publications (1)

Publication Number Publication Date
GB202204070D0 true GB202204070D0 (en) 2022-05-04

Family

ID=81344807

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2204070.3A Ceased GB202204070D0 (en) 2022-03-23 2022-03-23 Treatment

Country Status (2)

Country Link
GB (1) GB202204070D0 (en)
WO (1) WO2023180431A1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2717883T (en) * 2011-05-02 2017-04-25 Stichting Vumc Protection against endothelial barrier dysfunction through inhibition of the tyrosine kinase abl-related gene (arg)

Also Published As

Publication number Publication date
WO2023180431A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
GB202108224D0 (en) Treatment
GB202016058D0 (en) Therapeautic treatment
GB202003722D0 (en) Treatment
GB202002711D0 (en) Treatment
GB202319954D0 (en) Treatment
GB202319658D0 (en) Treatment
GB202319443D0 (en) Treatment
GB202318845D0 (en) Treatment
GB202311007D0 (en) Treatment
GB202304853D0 (en) Treatment
GB202218460D0 (en) Treatment
GB202214206D0 (en) Treatment
GB202212125D0 (en) Treatment
GB202204288D0 (en) Treatment
GB202204070D0 (en) Treatment
GB202201069D0 (en) Treatment
GB202212566D0 (en) Combination treatment
GB202304716D0 (en) New treatment
GB202210430D0 (en) New treatment
GB202206219D0 (en) New treatment
GB202208508D0 (en) Novel treatment
GB202104666D0 (en) COVID-19 treatment
GB202104416D0 (en) Treatment reginmens
GB202103957D0 (en) Treatment
GB202103122D0 (en) Treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)